KPL
Kwality Pharmaceuticals Limited
Kwality Pharmaceuticals Limited (KPL) financial statements and selected valuation metrics through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
kwalitypharma.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Stock price
₹3402.90
Market cap
3,531 Cr
Stock P/E
43.6
P/B
10.70
ROE (FY26)
20.4%
ROCE (FY26)
21.8%
Operating margin (FY26)
19.6%
Debt / equity (FY26)
0.40
OCF / EBITDA (FY26)
14.0%
OCF / EBITDA (3Y)
42.4%
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Indian drugmaker that makes injectable and tablet medicines, many of them supplied to other companies to sell under their own brands, mostly in export markets across Latin America, the Middle East and North Africa, Africa, Asia and the Commonwealth of Independent States (former Soviet countries).
Company snapshot
68thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
Positives
- ✓Return on equity of 20.4% — the company generates strong returns on shareholders' money.
Concerns
- ✗Only 42% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70 Cr | 78 Cr | 92 Cr | 80 Cr | 90 Cr | 84 Cr | 116 Cr | 111 Cr | 111 Cr | 123 Cr | 157 Cr | 162 Cr |
| Operating expenses (approx.) | 54 Cr | 61 Cr | 71 Cr | 63 Cr | 70 Cr | 67 Cr | 90 Cr | 87 Cr | 86 Cr | 93 Cr | 118 Cr | 121 Cr |
| EBITDA | 15 Cr | 17 Cr | 21 Cr | 17 Cr | 20 Cr | 17 Cr | 26 Cr | 24 Cr | 25 Cr | 30 Cr | 39 Cr | 41 Cr |
| OPM % | 21.9% | 21.4% | 22.4% | 21.7% | 21.8% | 20.7% | 22.4% | 21.7% | 22.8% | 24.3% | 24.7% | 25.3% |
| Other income | 0.23 Cr | 0.62 Cr | 0.58 Cr | 0.28 Cr | 0.22 Cr | 0.65 Cr | 0.77 Cr | 0.38 Cr | 0.90 Cr | 0.53 Cr | 1 Cr | 0.62 Cr |
| Interest | 2 Cr | 3 Cr | 3 Cr | 2 Cr | 3 Cr | 2 Cr | 2 Cr | 3 Cr | 3 Cr | 2 Cr | 3 Cr | 3 Cr |
| Depreciation | 5 Cr | 5 Cr | 5 Cr | 4 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr |
| Profit before tax | 8 Cr | 10 Cr | 6 Cr | 11 Cr | 13 Cr | 11 Cr | 19 Cr | 17 Cr | 18 Cr | 22 Cr | 32 Cr | 34 Cr |
| Tax % | 23.9% | 21.3% | 29.2% | 24.9% | 32.6% | 25.2% | 24.1% | 30.0% | 23.5% | 28.4% | 20.1% | 24.6% |
| Net profit | 6 Cr | 8 Cr | 4 Cr | 8 Cr | 8 Cr | 9 Cr | 14 Cr | 12 Cr | 14 Cr | 16 Cr | 25 Cr | 26 Cr |
| EPS (₹) | ₹5.99 | ₹7.39 | ₹4.08 | ₹8.04 | ₹8.15 | ₹8.21 | ₹13.95 | ₹11.49 | ₹13.60 | ₹15.42 | ₹24.39 | ₹24.69 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 98 Cr | 137 Cr | 166 Cr | 139 Cr | 262 Cr | 456 Cr | 251 Cr | 307 Cr | 370 Cr | 503 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 89 Cr | 126 Cr | 151 Cr | 125 Cr | 233 Cr | 285 Cr | 191 Cr | 241 Cr | 290 Cr | 385 Cr | Sign in free for the trailing twelve months |
| EBITDA | 9 Cr | 12 Cr | 16 Cr | 14 Cr | 29 Cr | 172 Cr | 60 Cr | 66 Cr | 80 Cr | 118 Cr | Sign in free for the trailing twelve months |
| OPM % | 9.0% | 8.5% | 9.4% | 10.2% | 11.0% | 37.6% | 24.0% | 21.6% | 21.7% | 23.5% | Sign in free for the trailing twelve months |
| Other income | 1 Cr | 0.80 Cr | 0.61 Cr | 4 Cr | 2 Cr | 4 Cr | 3 Cr | 2 Cr | 2 Cr | 3 Cr | Sign in free for the trailing twelve months |
| Interest | 2 Cr | 2 Cr | 2 Cr | 2 Cr | 3 Cr | 3 Cr | 6 Cr | 10 Cr | 10 Cr | 11 Cr | Sign in free for the trailing twelve months |
| Depreciation | 3 Cr | 3 Cr | 3 Cr | 4 Cr | 6 Cr | 11 Cr | 15 Cr | 20 Cr | 18 Cr | 20 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 6 Cr | 7 Cr | 11 Cr | 11 Cr | 21 Cr | 162 Cr | 26 Cr | 31 Cr | 54 Cr | 89 Cr | Sign in free for the trailing twelve months |
| Tax % | 42.0% | 39.4% | 30.7% | 24.8% | 30.0% | 25.8% | 24.6% | 24.1% | 26.5% | 24.7% | Sign in free for the trailing twelve months |
| Net profit | 3 Cr | 4 Cr | 8 Cr | 8 Cr | 15 Cr | 120 Cr | 19 Cr | 24 Cr | 40 Cr | 67 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | — | — | ₹7.28 | ₹8.02 | ₹14.60 | ₹115.64 | ₹18.16 | ₹22.76 | ₹38.36 | ₹64.90 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | Sign in free for the trailing twelve months |
Sign in free for the trailing twelve months
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr |
| Reserves | 20 Cr | 19 Cr | 27 Cr | 36 Cr | 51 Cr | 171 Cr | 190 Cr | 214 Cr | 254 Cr | 321 Cr |
| Borrowings | 18 Cr | 26 Cr | — | 31 Cr | — | — | 90 Cr | 98 Cr | 112 Cr | 130 Cr |
| Other liabilities | 27 Cr | 41 Cr | 68 Cr | 56 Cr | 105 Cr | 159 Cr | 64 Cr | 74 Cr | 72 Cr | 132 Cr |
| Total liabilities | 71 Cr | 96 Cr | 105 Cr | 133 Cr | 166 Cr | 341 Cr | 354 Cr | 394 Cr | 447 Cr | 592 Cr |
| Fixed assets (net) | 17 Cr | 20 Cr | 29 Cr | 43 Cr | 59 Cr | 104 Cr | 120 Cr | 139 Cr | 144 Cr | 150 Cr |
| CWIP | — | — | — | — | — | — | 14 Cr | 0 Cr | 0 Cr | 17 Cr |
| Investments | 4 Cr | 5 Cr | 5 Cr | 4 Cr | 5 Cr | 0.78 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Loans & advances | — | — | — | — | — | — | 10 Cr | 0 Cr | 0 Cr | 0 Cr |
| Inventories | 14 Cr | 15 Cr | 11 Cr | 22 Cr | 17 Cr | 53 Cr | 86 Cr | 78 Cr | 83 Cr | 78 Cr |
| Trade receivables | 23 Cr | 37 Cr | 38 Cr | 30 Cr | 36 Cr | 69 Cr | 72 Cr | 114 Cr | 154 Cr | 280 Cr |
| Cash & bank | 3 Cr | 2 Cr | 1 Cr | 2 Cr | 6 Cr | 13 Cr | 3 Cr | 2 Cr | 12 Cr | 0.74 Cr |
| Other assets | 11 Cr | 17 Cr | 20 Cr | 32 Cr | 43 Cr | 100 Cr | 47 Cr | 60 Cr | 53 Cr | 66 Cr |
| Total assets | 71 Cr | 96 Cr | 105 Cr | 133 Cr | 166 Cr | 341 Cr | 354 Cr | 394 Cr | 447 Cr | 592 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 4 Cr | -0.57 Cr | 14 Cr | 6 Cr | 27 Cr | 64 Cr | 41 Cr | 43 Cr | 53 Cr | 17 Cr |
| Cash from investing | -7 Cr | -6 Cr | -12 Cr | -18 Cr | -23 Cr | -63 Cr | -48 Cr | -26 Cr | -29 Cr | -35 Cr |
| Cash from financing | 5 Cr | 5 Cr | -2 Cr | 12 Cr | 0.77 Cr | 6 Cr | 0.99 Cr | -17 Cr | -14 Cr | 7 Cr |
| Net cash flow | 2 Cr | -1 Cr | -0.21 Cr | 0.14 Cr | 4 Cr | 7 Cr | -6 Cr | -0.81 Cr | 10 Cr | -11 Cr |
| Free cash flow (OCF − Capex) | -2 Cr | -7 Cr | 2 Cr | -15 Cr | 3 Cr | 9 Cr | -6 Cr | 13 Cr | 28 Cr | -32 Cr |
Ratios
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 17.3% | 17.3% | 35.4% | 17.6% | 39.2% | 90.8% | 10.9% | 12.9% | 17.1% | 21.8% |
| ROE % | 13.4% | 15.8% | 20.2% | 18.5% | 24.8% | 66.2% | 9.7% | 10.7% | 15.2% | 20.4% |
| Debtor days | 84 | 98 | 84 | 79 | 50 | 55 | 104 | 136 | 152 | 203 |
| Inventory days | 70 | 53 | 36 | 89 | 38 | 97 | 277 | 186 | 184 | 118 |
| Days payable | 65 | 78 | — | 91 | — | — | 113 | 105 | 123 | 154 |
| Cash conversion cycle | 89 | 73 | 120 | 77 | 88 | 153 | 268 | 217 | 213 | 167 |
| OCF / EBITDA % | 48.7% | -4.9% | 86.4% | 43.4% | 92.6% | 37.6% | 68.8% | 64.8% | 65.6% | 14.0% |
| OCF / EBITDA % (3 years) | — | — | 47.8% | 46.1% | 79.1% | 45.3% | 50.9% | 49.9% | 66.3% | 42.4% |
| Debt / equity | 0.73 | 0.91 | 0.00 | 0.70 | 0.00 | 0.00 | 0.45 | 0.44 | 0.43 | 0.40 |
| Current ratio | 1.28 | 1.21 | 1.24 | 1.31 | 1.35 | 1.75 | 1.65 | 1.60 | 1.67 | 1.80 |
| Net debt / EBITDA | 1.75 | 2.10 | -0.09 | 2.11 | -0.20 | -0.08 | 1.45 | 1.45 | 1.25 | 1.10 |